AMGN Amgen

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
• • NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023
• • Strategic shift: Acquisition of Horizon Therapeutics with stock plans merged, ending Horizon plans for future grants as of Oct 6, 2023
• • Quantitative metric: 11,230,989 total securities issuable under Amgen and acquired equity plans, weighted-average exercise price $234.45
• • Noteworthy fact: Performance units granted in 2023-2025 can yield up to 200% of target shares based on performance goals

Management Discussion & Analysis

• • Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
• • Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024
• • Dividends per share increased 6% YoY to $2.38 in 2025 from $2.25 in 2024
• • No stock repurchases in 2025, $200M repurchased in 2024, $6.8B repurchase authorization remains
• • Management confident in liquidity from operations, debt markets, and existing cash for capital needs and shareholder returns

Risk Factors

• • Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
• • Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals
• • Supply chain/operational vulnerability: Multi-jurisdictional patent litigation delays marketing; UPC actions and EPO oppositions prolong product launches like Repatha and PAVBLU
• • Competitive risk: Multiple biosimilar patent infringement lawsuits filed against five companies including Amneal, Hikma, Dr. Reddy’s, Alkem seeking to enter U.S. market for Prolia/XGEVA
• • Financial risk: $1.8B final U.S. repatriation tax payment made in 2025 under 2017 Tax Act, material cash outflow impacting liquidity planning

What are the latest AMGN SEC filings in 2026?

Amgen (AMGN) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on May 1, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AMGN file its most recent 10-K annual report?

Amgen (AMGN) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AMGN 10-Q quarterly reports?

Amgen (AMGN)'s most recent 10-Q quarterly report was filed on May 1, 2026. SignalX displays every AMGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AMGN filed recently?

Amgen (AMGN)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AMGN insider trading activity (Form 4)?

SignalX aggregates every AMGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AMGN file with the SEC?

Amgen (AMGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AMGN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Amgen (AMGN).

What is AMGN's SEC CIK number?

Amgen (AMGN)'s SEC CIK (Central Index Key) number is 318154. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 318154 to look up all AMGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AMGN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Amgen (AMGN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.